(NASDAQ: SYRE) Spyre Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.13%.
Spyre Therapeutics's earnings in 2024 is -$185,981,000.On average, 4 Wall Street analysts forecast SYRE's earnings for 2024 to be -$186,661,974, with the lowest SYRE earnings forecast at -$212,312,123, and the highest SYRE earnings forecast at -$143,234,495. On average, 4 Wall Street analysts forecast SYRE's earnings for 2025 to be -$175,360,671, with the lowest SYRE earnings forecast at -$223,486,446, and the highest SYRE earnings forecast at -$99,553,053.
In 2026, SYRE is forecast to generate -$124,441,316 in earnings, with the lowest earnings forecast at -$124,441,316 and the highest earnings forecast at -$124,441,316.